BelizeMe, I don't always agree with some of the negative spin you often put in your posts, but the math usually adds up. This time I have to disagree.
If MDT owns 30% of the shares, they are still outstanding shares. They would effectively be paying themselves for those shares so they "get a refund" so to speak on the overall buyout price, but it does not discount the value of each share (including mine and yours)by 30%. It is still total buyout price divided by outstanding share count.
Message in reply to:
Everyone keeps valuing this robot with Medtronic like they don’t already own 30% of it. That will get subtracted off any BO offer. So again, $2 billion valuation minus 1/3 of IP already paid for by MDT comes down to $1.3 B and around nine bucks a share. Woo hoo.
If you were in the medical device industry and in hospitals you would realize that the intuitive SP robot makes up less than 5% of their capital and disposable business.
Robots that have sold for $3.5 B and up we’re robots that would handle the entire amount of indications for the procedures.
In other words, Auris doesn’t need a second robot to come in and handle the more complex indications. Same with the Mazor spine robot.
News 
Market Data 
Discover 
